Linked Life Data

7836740

Source:http://linkedlifedata.com/resource/pubmed/id/7836740

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7836740rdf:typepubmed:Citationlld:pubmed
pubmed-article:7836740lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C0225336lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C0934502lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C0221912lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C0079717lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C0209606lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C0600210lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:7836740lifeskim:mentionsumls-concept:C0050156lld:lifeskim
pubmed-article:7836740pubmed:issue4lld:pubmed
pubmed-article:7836740pubmed:dateCreated1995-2-27lld:pubmed
pubmed-article:7836740pubmed:abstractTextThe cutaneous lymphocyte-associated Ag (CLA) is expressed by a subset of circulating memory/effector T cells and by the vast majority of skin-infiltrating T cells. CLA is thought to target skin-associated T cells to inflammatory skin sites by interacting with endothelial cell ligand E-selectin (CD62E). We have examined adhesion molecules involved in the migration of human CLA+ and CLA- memory/effector T lymphocytes through IL-1- and TNF-alpha-activated and nonactivated HUVEC layers under static (nonflow) conditions. CLA-enriched memory/effector T lymphocytes migrated more actively across cytokine-activated HUVEC than CLA-depleted memory/effector T cells. This enhanced migration is dependent on the CLA/E-selectin interaction. mAb to very late Ag-4 (VLA-4) and vascular cell adhesion molecule-1 (VCAM-1) blocked the migration of CLA-enriched, but not of CLA-depleted, T cells across activated HUVEC. The observation that anti-VLA-4 and anti-CLA mAb did not show additional inhibition supports the concept that CLA and VLA-4 are sequentially involved in the extravasation. The fact that only CLA+ T cells were inhibited by the anti-VLA-4 mAb suggests that, in this system, CLA engagement is required for using the VLA-4/VCAM-1 pathway. Our studies demonstrate that CLA+ T cells use LFA-1/intercellular leukocyte adhesion molecule-1 (ICAM-1) for transmigration but that CLA expression is not required for the LFA-1/ICAM-1-dependent transmigration because anti-CD18/CD11a mAbs and anti-ICAM-1 mAbs were able to block T cell migration regardless of the activation state of HUVEC or the CLA expression by T cells. Taken together, our results suggest that CLA has a homing function in conducting the T cell to interact with LFA-1/ICAM-1 and/or VLA-4/VCAM-1; this results in enhanced adhesion and migration across cytokine-activated endothelial cells.lld:pubmed
pubmed-article:7836740pubmed:languageenglld:pubmed
pubmed-article:7836740pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7836740pubmed:citationSubsetAIMlld:pubmed
pubmed-article:7836740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7836740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7836740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7836740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7836740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7836740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7836740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7836740pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7836740pubmed:statusMEDLINElld:pubmed
pubmed-article:7836740pubmed:monthFeblld:pubmed
pubmed-article:7836740pubmed:issn0022-1767lld:pubmed
pubmed-article:7836740pubmed:authorpubmed-author:BlaserKKlld:pubmed
pubmed-article:7836740pubmed:authorpubmed-author:MosesSSlld:pubmed
pubmed-article:7836740pubmed:authorpubmed-author:HausenGGlld:pubmed
pubmed-article:7836740pubmed:authorpubmed-author:PickerL JLJlld:pubmed
pubmed-article:7836740pubmed:authorpubmed-author:Santamaria...lld:pubmed
pubmed-article:7836740pubmed:authorpubmed-author:Perez...lld:pubmed
pubmed-article:7836740pubmed:issnTypePrintlld:pubmed
pubmed-article:7836740pubmed:day15lld:pubmed
pubmed-article:7836740pubmed:volume154lld:pubmed
pubmed-article:7836740pubmed:ownerNLMlld:pubmed
pubmed-article:7836740pubmed:authorsCompleteYlld:pubmed
pubmed-article:7836740pubmed:pagination1543-50lld:pubmed
pubmed-article:7836740pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:meshHeadingpubmed-meshheading:7836740-...lld:pubmed
pubmed-article:7836740pubmed:year1995lld:pubmed
pubmed-article:7836740pubmed:articleTitleMigration of skin-homing T cells across cytokine-activated human endothelial cell layers involves interaction of the cutaneous lymphocyte-associated antigen (CLA), the very late antigen-4 (VLA-4), and the lymphocyte function-associated antigen-1 (LFA-1).lld:pubmed
pubmed-article:7836740pubmed:affiliationSwiss Institute of Allergy and Asthma Research, Davos.lld:pubmed
pubmed-article:7836740pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7836740pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7836740lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7836740lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7836740lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7836740lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7836740lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7836740lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7836740lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7836740lld:pubmed